Applied DNA Sciences Inc APDN.OQ reported a quarterly adjusted loss of 32 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of two analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -35 cents to -33 cents per share.
Revenue rose 4.2% to $813.11 thousand from a year ago; analysts expected $899.00 thousand.
Applied DNA Sciences Inc's reported EPS for the quarter was a loss of 32 cents.
The company reported a quarterly loss of $3.3 million.
Applied DNA Sciences Inc shares had fallen by 71.6% this quarter and lost 98.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"
This summary was machine generated from LSEG data December 17 at 10:03 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.34 | -0.32 | Beat |
Jun. 30 2024 | -0.35 | 0.47 | Beat |
Mar. 31 2024 | -4.50 | -5.31 | Missed |
Dec. 31 2023 | -6.20 | -1.80 | Beat |
Comments